VERTEX PHARMACEUTICALS INC / MA Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments of $29.48 million as of 2018-12-31, per its 10-K filed 2020-02-13.
Discontinued › Notes › Leases
us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments · last filed 2020-02-13
- 2018-12-31: Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments $29.48M.
- 2017-12-31: Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments $43.03M.
- 2016-12-31: Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments $54.40M.
- 2015-12-31: Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments $58.47M.
| Period end | Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments |
|---|---|
| 2018-12-31 | $29.48M 10-K · filed 2020-02-13 |
| 2017-12-31 | $43.03M 10-K · filed 2018-02-15 |
| 2016-12-31 | $54.40M 10-K · filed 2017-02-23 |
| 2015-12-31 | $58.47M 10-K · filed 2016-02-16 |
| 2014-12-31 | $57.10M 10-K · filed 2015-02-13 |
| 2014-09-30 | $60.32M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $64.76M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $67.82M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $65.65M 10-K · filed 2014-02-11 |
| 2013-09-30 | $53.81M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $38.75M 10-Q · filed 2013-08-02 |
| 2012-12-31 | $28.88M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |